Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2022 | Risk-adjusted safety analysis of pacritinib for patients with MF

Naveen Pemmaraju • 5 Jun 2022
ASCO 2022
Myelofibrosis Myeloproliferative Neoplasms Fedratinib Pacritinib Ruxolitinib
PAC203 PERSIST-2

In this video, Naveen Pemmaraju, MD, University of Texas MD Anderson Cancer Center, Houston, TX, discusses the risk-adjusted safety analysis of pacritinib, a novel JAK inhibitor, for the treatment of patients with myelofibrosis (MF). Dr Pemmaraju first provides some background information on the approval of pacritinib and then discusses the safety and efficacy of pacritinib versus best available therapy in patients with MF. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.

More from Naveen Pemmaraju

1:40
TAG-AZA-VEN in the treatment of patients with newly diagnosed CD123+ AML
Naveen Pemmaraju • 11 Dec 2023
1:29
Exciting developments in the field of BPDCN
Naveen Pemmaraju • 11 Dec 2023
1:58
TRANSFORM-1: navitoclax + ruxolitinib vs placebo + ruxolitinib in patients with untreated MF
Naveen Pemmaraju • 11 Dec 2023
1:15
Exploring the evolving treatment landscape of myelofibrosis
Naveen Pemmaraju • 3 Jun 2023

Related Videos

2:05
Donor lymphocyte infusion for relapsed myelofibrosis in the post-alloSCT setting
Alex Rampotas • 16 Apr 2024
2:52
JAK inhibitor combination therapy for the treatment of myelofibrosis
Ruben Mesa • 9 Dec 2023
1:30
XPORT-MF-034: selinexor + ruxolitinib combination therapy for MF
John Mascarenhas • 10 Dec 2023
1:38
Pelabresib plus ruxolitinib for the treatment of intermediate- and high-risk myelofibrosis
John Mascarenhas • 10 Dec 2023
The content of VJHemOnc is intended for healthcare professionals